The Geneva Foundation

The Geneva Foundation, a 501(c)(3) nonprofit research organization headquartered in Tacoma, Washington, serves as a prime contractor and recipient on federal biomedical research and clinical support services for defense and health agencies, with 86% of recent awards in the prime role and no SBA set-asides across its portfolio. The foundation operates across military medical research, combat casualty care, infectious disease, cancer therapeutics, and clinical trial execution, competing in full and open competition across contract and grant vehicles.

The Defense Health Agency and Department of the Army Medical Command dominate Geneva's customer base, accounting for 85% of recent awards by count. By combined potential value, the National Institute of Allergy and Infectious Diseases leads at $109.1 million across 22 awards, followed by the Army Medical Command at $74.8 million (170 awards) and the Navy Bureau of Medicine and Surgery at $69.5 million (9 awards). The Defense Health Agency places 173 awards totaling $21.8 million in potential value. Geneva has worked with 35 distinct federal agencies across the DoD, Department of Veterans Affairs, Health and Human Services, and other civilian agencies.

Recent prime contract awards exemplify Geneva's capability scope: a $561,042 firm fixed-price contract with the Air Force Defense Finance and Accounting Service for research on NVG-291 protein tyrosine phosphatase inhibitor therapy for blast-induced hearing loss (completed September 2026), a $963,936 purchase order from Veterans Integrated Service Network 20 for animal care technician services at the VA Puget Sound Health Care System through 2029, a $748,050 definitive contract from the Office of the Assistant Secretary for Preparedness and Response for development of a Multiorgan Extracorporeal Life Support (MELS) platform, and a $1,774,748 Defense Health Agency definitive contract for Connected and Autonomous Procedure Support Tools for Combat Trauma and Mass Casualty Management. Geneva holds a General Services Administration Federal Supply Schedule contract with a $5 million ceiling and special item numbers 541715 (engineering R&D services) and OLM, carrying 38 labor categories spanning administrative assistants ($39.94/hr with high school plus two years experience) through research pharmacists ($163.35/hr with Ph.D. plus three years experience), with no security-cleared positions. The foundation also maintains a Defense Advanced Research Projects Agency Other Transaction IDV with a $999,146 ceiling awarded December 2023 for low-intensity focused ultrasound modulation of deep brain structures to enhance REM sleep, though no task orders have issued to date.

On the Army side, Geneva places work under Indefinite Delivery Contract W81XWH11D0049 (60 task orders, $36.4 million combined potential value) and Blanket Purchase Agreement W911QY16A0014 (35 task orders, $6.3 million). Recent Army Medical Command awards include sole-source and competitive purchase orders for clinical research assistant positions, physical therapy research support, and musculoskeletal and traumatic brain injury studies at Madigan Army Medical Center, Brooke Army Medical Center, and Fort Sam Houston.

Federal grant work reflects Geneva's research leadership in military medical priorities. The Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) has awarded Geneva $4.82 million for patient-matched segmental defect implant systems with mechanobiologic activation (July 2025), $4.4 million for extracorporeal immunomodulation to reduce inflammation after severe burns and septicemia (November 2025), $4.676 million for innate immunome-targeted therapeutics after hemorrhage (July 2023), and $1.857 million for a multiplex testing platform to detect and identify Plasmodium species infections (June 2024). The Uniformed Services University of the Health Sciences has awarded Geneva multi-million-dollar cooperative agreements including $2.457 million for the Musculoskeletal Injury Rehabilitation Research for Operational Readiness (MIRROR) initiative (October 2025, with a sub-award to The Henry M. Jackson Foundation for the Advancement of Military Medicine), $2.3 million for Blood Transfusion Optimization (January 2026), and $1,467,910.92 for the Blast Overpressure Exposure Longitudinal Study (August 2025). Additional DHA project grants support cancer immunotherapy (CAR T-cells for TP53-mutant breast cancer, $747,394), malaria vaccine development ($638,820 mRNA multivalent approach, September 2023), and translational oncology research across lymphoma, pancreatic cancer, colorectal cancer, prostate cancer, and lung cancer. The National Institute of Allergy and Infectious Diseases funded a $377 thousand project on genetic markers of susceptibility to intracellular bacterial infection using the Collaborative Cross mouse model (August 2022).

Activity has grown from 31 awards in 2022 to a peak of 50 in 2024, moderating to 38 in 2025 and 15 in the first nine months of 2026. Fifty-eight awards (combined potential value $2.6 million) complete within the next twenty-four months, presenting recompete exposure concentrated in smaller dollar-value work. Combined obligated dollars across all awards ($644.1 million) exceed combined potential value ($312.9 million), reflecting multi-year project extensions and incremental funding modifications common in research grant administration.

Geneva operates as a prime on 570 awards (86%) and subcontracts on 96 awards (14%). Named subcontract primes include Teledyne Scientific & Imaging LLC (wearable neurotechnology for insomnia treatment, multiple incremental funding awards July 2025), Kitware Inc. (DARPA TRIAGE Challenge and aligned moral language models), Serco Inc. (Holistic Health and Fitness program support via Personnel Life-Cycle Support Services MAC), and Battelle Memorial Institute (CET-RAIDIR program evaluation). On the grant side, Geneva acts as recipient and frequently sub-awards to research universities and medical institutions: The Henry M. Jackson Foundation for the Advancement of Military Medicine (musculoskeletal injury rehabilitation, blood transfusion optimization, multiple clinical outcomes research programs), The Johns Hopkins University (immune function assays for vaccine efficacy studies), Stanford University (PAX3-FOXO1 fusion oncogene regulation in rhabdomyosarcoma), Vanderbilt University Medical Center (bunyavirus and picornavirus pandemic preparedness), University of Utah (telehealth physical therapy, pain management, prosthetic optimization), and dozens of other academic medical centers. SCI-reportable federal service contract invoicing totaled $454 thousand in FY2024 across 2.7 FTEs on three prime records; the SCI dataset is sparse and does not reflect Geneva's full federal services footprint, which is dominated by research grants and project-based contracting rather than labor-hour service contracts above the reporting threshold.

The foundation's primary NAICS codes reflect its research orientation: All Other Professional, Scientific, and Technical Services (76 awards), Research and Development in the Physical, Engineering, and Life Sciences except Biotechnology (55 awards), Research and Development in Biotechnology except Nanobiotechnology (14 awards), and Research and Development in the Physical, Engineering, and Life Sciences except Nanotechnology and Biotechnology (21 awards). PSC coding mirrors clinical and research delivery: Support–Professional Other (75 awards), Health R&D Services across basic, applied, and experimental development and healthcare services (combined 23 awards), and Support–Professional Engineering/Technical (8 awards). Geneva's competitive posture is full and open; the foundation does not hold set-asides and does not carry minority-owned, women-owned, veteran-owned, or HUBZone designations.